|
1
|
Gaist D, Jeppesen U, Andersen M, Garcia
Rodriguez LA, Hallas J and Sindrup SH: Statins and risk of
polyneuropathy: A case-control study. Neurology. 58:1333–1337.
2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Emad M, Arjmand H, Farpour HR and Kardeh
B: Lipid-lowering drugs (statins) and peripheral neuropathy.
Electron Physician. 10:6527–6533. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Warendorf JK, Vrancken A, van Eijk RPA,
Visser NA, van den Berg LH and Notermans NC: Statins do not
increase risk of polyneuropathy: A case-control study and
literature review. Neurology. 92:e2136–e2144. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Superko HR, Zhao XQ, Hodis HN and Guyton
JR: Niacin and heart disease prevention: Engraving its tombstone is
a mistake. J Clin Lipidol. 11:1309–1317. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Calderon-Ospina CA and Nava-Mesa MO: B
Vitamins in the nervous system: Current knowledge of the
biochemical modes of action and synergies of thiamine, pyridoxine,
and cobalamin. CNS Neurosci Ther. 26:5–13. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gasperi V, Sibilano M, Savini I and Catani
MV: Niacin in the central nervous system: An update of biological
aspects and clinical applications. Int J Mol Sci.
20(974)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bolino A, Piguet F, Alberizzi V,
Pellegatta M, Rivellini C, Guerrero-Valero M, Noseda R, Brombin C,
Nonis A, D'Adamo P, et al: Niacin-mediated Tace activation
ameliorates CMT neuropathies with focal hypermyelination. EMBO Mol
Med. 8:1438–1454. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kessler DA: Introducing MEDWatch. A new
approach to reporting medication and device adverse effects and
product problems. JAMA. 269:2765–2768. 1993.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lehrer S and Rheinstein PH: Nonsteroidal
anti-inflammatory drugs (NSAIDs) reduce suicidal ideation and
depression. Discov Med. 28:205–212. 2019.PubMed/NCBI
|
|
10
|
Craigle V: MedWatch: The FDA safety
information and adverse event reporting program. J Med Library
Association. 95(224)2007.
|
|
11
|
Bohm R, Hocker J, Cascorbi I and Herdegen
T: OpenVigil-free eyeballs on AERS pharmacovigilance data. Nat
Biotechnol. 30:137–138. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Böhm R, von Hehn L, Herdegen T, Klein HJ,
Bruhn O, Petri H and Höcker J: OpenVigil FDA-Inspection of U.S.
American Adverse Drug Events Pharmacovigilance Data and Novel
Clinical Applications. PLoS. One. 11(e0157753)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Coloma PM, Becker B, Sturkenboom MC, van
Mulligen EM and Kors JA: Evaluating social media networks in
medicines safety surveillance: Two case studies. Drug Saf.
38:921–930. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Evans SJ, Waller PC and Davis S: Use of
proportional reporting ratios (PRRs) for signal generation from
spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug
Saf. 10:483–486. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Hauben M, Reich L, DeMicco J and Kim K:
‘Extreme duplication’ in the US FDA Adverse Events Reporting System
database. Drug Saf. 30:551–554. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mukhtar RY, Reid J and Reckless JP:
Pitavastatin. Int J Clin Pract. 59:239–252. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Alavijeh MS, Chishty M, Qaiser MZ and
Palmer AM: Drug metabolism and pharmacokinetics, the blood-brain
barrier, and central nervous system drug discovery. NeuroRx.
2:554–571. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rosch PJ: Peripheral neuropathy. Lancet.
364:1663–1665. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Donaghy M: Assessing the risk of
drug-induced neurologic disorders: Statins and neuropathy.
Neurology. 58:1321–1322. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Koslik HJ, Meskimen AH and Golomb BA:
Physicians' Experiences as patients with statin side effects: A
case series. Drug Saf Case Rep. 4(3)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Weimer LH and Sachdev N: Update on
medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep.
9:69–75. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Malfitano AM, Marasco G, Proto MC, Laezza
C, Gazzerro P and Bifulco M: Statins in neurological disorders: An
overview and update. Pharmacol Res. 88:74–83. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lloyd-Jones DM: Niacin and HDL
cholesterol-time to face facts. N Engl J Med. 371:271–273.
2014.PubMed/NCBI View Article : Google Scholar
|
